Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

SoftOx Solutions

Mindre end 1K følgere

SOFTX

Euronext Growth Oslo

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Investorkonsensus

SoftOx Solutions is a Norwegian medical technology company. The company has developed a proprietary solution based on acetic acid for the treatment of chronic wounds in patients. The solution is used to eliminate infections associated with biofilms, which consist of different clusters of bacteria. Part of the drug development is done in collaboration with other research institutes. SoftOx Solutions was founded in 2012 and is headquartered in Oslo, Norway.

Læs mere
Markedsværdi
-
Aktieomsætning
-
Omsætning
7,91 mio.
EBIT %
-410,37 %
P/E
-
Udbytteafkast, %
-
Finanskalender
15.12
2025

Ekstraordinær generalforsamling '25

5.3
2026

Årsrapport '25

24.6
2026

Generalforsamling '26

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelse5.12.2025, 17.11

SoftOx Solutions AS: New Share Capital

SoftOx Solutions
Selskabsmeddelelse28.11.2025, 13.32

SoftOx Solutions AS: Notice of Extraordinary General Assembly

SoftOx Solutions
Selskabsmeddelelse28.11.2025, 13.31

SoftOx Solutions AS: SoftOx Solutions AS exercises on the financing facility with Long State Investments Limited

SoftOx Solutions

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse26.11.2025, 07.00

SoftOx Solutions AS: Third Quarter Report 2025

SoftOx Solutions
Selskabsmeddelelse14.11.2025, 07.35

SoftOx Solutions AS: GMP Drug Substance Successfully Manufactured - Key Milestone for CF and EDF Clinical Programs

SoftOx Solutions
Selskabsmeddelelse16.10.2025, 10.26

SoftOx Solutions AS: SoftOx submits Phase 1 Clinical Trial Application under the European Defence Fund (EDF) Program

SoftOx Solutions
Selskabsmeddelelse13.10.2025, 06.11

SoftOx Solutions AS: New Share Capital

SoftOx Solutions
Selskabsmeddelelse7.10.2025, 19.17

SoftOx Solutions AS: Private Placement resolved

SoftOx Solutions
Selskabsmeddelelse3.10.2025, 13.23

SoftOx Solutions AS: New Share Capital

SoftOx Solutions
Selskabsmeddelelse1.10.2025, 12.35

SoftOx Solutions AS: Clinical Trial Application for Dose Escalation / Cystic Fibrosis Phase 2a - Important Milestone Achieved

SoftOx Solutions
Selskabsmeddelelse25.9.2025, 15.51

SoftOx Solutions AS: Clarification on Placement Commission

SoftOx Solutions
Selskabsmeddelelse25.9.2025, 13.08

SoftOx Solutions AS: Private Placements resolved

SoftOx Solutions
Selskabsmeddelelse23.9.2025, 07.07

SoftOx Solutions AS: SoftOx builds momentum: CF trial strategy reinforced by HOCl stability breakthrough

SoftOx Solutions
Selskabsmeddelelse23.9.2025, 06.00

SoftOx Solutions AS: SoftOx builds momentum: CF trial strategy reinforced by HOCl stability breakthrough

SoftOx Solutions
Selskabsmeddelelse17.9.2025, 06.00

SoftOx Solutions AS: Second Quarter/Half-Year Report 2025

SoftOx Solutions
Selskabsmeddelelse11.9.2025, 13.59

SoftOx Solutions AS: Softox Solutions AS exercises on the financing facility with Long State Investments Limited

SoftOx Solutions
Selskabsmeddelelse8.9.2025, 10.07

SoftOx Solutions AS: Presentation Deck and link to today's Investor Update

SoftOx Solutions
Selskabsmeddelelse8.9.2025, 06.00

SoftOx Solutions AS: Reminder - Investor Update in connection with the Refinement of the Clinical Focus into Chronic Lung Disease Treatment

SoftOx Solutions
Selskabsmeddelelse3.9.2025, 10.39

SoftOx Solutions AS: Investor Update in connection with the Refinement of the Clinical Focus into Chronic Lung Disease Treatment

SoftOx Solutions
Selskabsmeddelelse2.9.2025, 06.59

SoftOx Solutions AS: Refines Clinical Focus and Advances Into Chronic Lung Disease Treatments

SoftOx Solutions
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.